Cytokine signaling from the tumor microenvironment can allow leukemia cells to survive targeted imatinib therapy, in the first report of a non-autonomous resistance mechanism. Targeted cancer ...

A recent phase II study showed that dasatinib, a novel oral agent active against BCR-ABL, induce remarkable responses in patients with CML-CP resistant or intolerant to imatinib. The study ...

and imatinib-resistant (2L/3L) GIST patient-derived xenograft models. Sixty percent of patients develop resistance to imatinib within two years and ziftomenib has the potential to delay the onset ...